Sarcomas/TGCT | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCC

October 31st 2022

Marcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .

Salarius Pauses Phase 1/2 Trial Investigating Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Following Death

October 19th 2022

Salarius Pharmaceuticals has voluntarily paused enrollment of new patients into a phase 1/2 trial investigating seclidemstat in patients with Ewing sarcoma, sarcomas with FET-family translocations, and myxoid liposarcoma due to the death of a patient.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma

October 16th 2022

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

Socioeconomic Disparities Associated With Worse OS in Head and Neck Cutaneous Soft Tissue Sarcoma

October 11th 2022

R. Lor Randall, MD, FACS, discusses how disparities may lead to worse outcomes for patients diagnosed with head and neck cutaneous soft tissue sarcomas.

Phase 2 ENVASARC Trial of Envafolimab With and Without Ipilimumab in Sarcoma to Continue

October 7th 2022

An independent data monitoring committee has recommended that the phase 2 ENVASARC trial examining envafolimab with and without ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma continue as planned.

FDA Grants Fast Track Designation to AL102 for Progressing Desmoid Tumors

September 27th 2022

The FDA has granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.

Desmoid Tumors: The Tumor That Isn’t a Cancer

September 27th 2022

Desmoid tumors, also known as aggressive fibromatosis, share some characteristics with cancers, specifically unchecked cell growth. However, it is not accurate to call them a cancer.

FDA Streamlines Regulatory Process for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma

September 15th 2022

The FDA has granted a fast track designation to envafolimab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma and myxofibrosarcoma who have progressed on 1 or 2 prior lines of chemotherapy.

FDA Grants Orphan Drug Designation to DUNP19 for Osteosarcoma

September 13th 2022

The FDA has granted an orphan drug designation to DUNP19 for the treatment of osteosarcoma.

Nirogacestat Improves PFS in Progressing Desmoid Tumors

September 10th 2022

Nirogacestat led to a 71% reduction in the risk of disease progression or death compared with placebo in patients with progressive desmoid tumors.

AVA6000 Granted FDA Orphan Drug Status for Soft Tissue Sarcoma

September 8th 2022

The FDA has granted an orphan drug designation to AVA6000, a modified form of doxorubicin, for the treatment of patients with soft tissue sarcoma.

FDA Grants Fast Track Designation to AMB-05X in Tenosynovial Giant Cell Tumors

September 7th 2022

The FDA has granted fast track designation to AMB-05X for the treatment of patients with tenosynovial giant cell tumors.

Surgical Complications Unrelated to Timing of Neoadjuvant Chemotherapy in Lower-Extremity Sarcomas

September 6th 2022

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

Patients With Bone Sarcomas of Lower-Extremity and Non-Private Insurance Linked With Higher Amputation Rates, Worse Outcomes

September 5th 2022

Amputation is an independent predictor of poor outcomes among patients with high-grade bone sarcoma of lower extremity, and non-private insurance was found to be linked with increased likelihood of amputation and an advanced stage at presentation in this patient population.

Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors

August 29th 2022

Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas

August 23rd 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.

INBRX-109 Granted Orphan Drug Designation in Europe for Chondrosarcoma

August 16th 2022

The European Commission has granted an orphan medicinal product designation to INBRX-109 for use as a potential therapeutic option in patients with chondrosarcoma.

Dr Wagner or the Potential Value of Immunotherapy in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Dr Wagner on Molecular Pathways in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.